{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T15:26:43Z","timestamp":1648999603013},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s00108-005-1413-x","type":"journal-article","created":{"date-parts":[[2005,5,9]],"date-time":"2005-05-09T10:06:02Z","timestamp":1115633162000},"page":"659-670","source":"Crossref","is-referenced-by-count":0,"title":["Neue Medikamente zur Behandlung systemischer Mykosen"],"prefix":"10.1007","volume":"46","author":[{"given":"I.","family":"Schedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1413_CR1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","volume":"33","author":"Ally","year":"2001","unstructured":"Ally R, Schurmann D, Kreisel W (2001) A randomized, doublesive aspergillosis (IA) caused by Aspergillus terreus: multi- blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33:1447\u20131454","journal-title":"Clin Infect Dis"},{"key":"1413_CR2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/01.mop.0000150630.83442.e1","volume":"17","author":"Antachopoulos","year":"2005","unstructured":"Antachopoulos C, Walsh TJ (2005) New agents for invasive mycoses in children. Curr Opin Pediatr 17:78\u201387","journal-title":"Curr Opin Pediatr"},{"key":"1413_CR3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00001432-200112000-00004","volume":"Dis14","author":"Arathoon","year":"2001","unstructured":"Arathoon EG (2001) Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis14:685\u2013691","journal-title":"Curr Opin Infect"},{"key":"1413_CR4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","volume":"46","author":"Arathoon","year":"2002","unstructured":"Arathoon EG, Gotuzzo E, Noriega LM et al. (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 46:451\u2013457","journal-title":"Antimicrob Agents Chemother"},{"key":"1413_CR5","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/JCM.40.6.2228-2230.2002","volume":"40","author":"Bachmann","year":"2002","unstructured":"Bachmann SP, Patterson TF, Lopez-Ribot JL (2002) In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 40:2228\u20132230","journal-title":"J Clin Microbiol"},{"key":"1413_CR6","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/01.TP.0000089109.42239.75","volume":"76","author":"Baden","year":"2003","unstructured":"Baden LR, Katz JT, Fishman JA (2003) Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 76:1632\u20131637","journal-title":"Transplantation"},{"key":"1413_CR7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199401273300407","volume":"330","author":"Como","year":"1994","unstructured":"Como JA, Dismukes WE (1994) Oral azole drugs as systemic antifungal therapy. N Engl J Med 330(4):263\u2013272","journal-title":"N Engl J Med"},{"key":"1413_CR8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/40.5.611","volume":"40","author":"Denning","year":"1997","unstructured":"Denning DW (1997) Echinocandins and pneumocandins \u2014 a new antifungal class with a novel mode of action (1997). J Antimicrob Chemother 40:611\u2013614","journal-title":"J Antimicrob Chemother"},{"key":"1413_CR9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"Denning","year":"2002","unstructured":"Denning DW, Ribaud P, Milpied N (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563\u2013571","journal-title":"Clin Infect Dis"},{"key":"1413_CR10","doi-asserted-by":"crossref","unstructured":"Eriksson U, Seifert B, Schaffner A (2001) Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial Br Med J 322:579\u2013585","DOI":"10.1136\/bmj.322.7286.579"},{"key":"1413_CR11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0733-8635(03)00024-X","volume":"21","author":"Gupta","year":"2003","unstructured":"Gupta AK, Tomas E (2003) New antifungal agents. Dermatol Clin 21(3):565\u2013576","journal-title":"Dermatol Clin"},{"key":"1413_CR12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408\u2013415","journal-title":"N Engl J Med"},{"key":"1413_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","volume":"337","author":"Horst","year":"1997","unstructured":"Horst CM van der, Saag MS, Cloud GA (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337(1):15\u201321","journal-title":"N Engl J Med"},{"key":"1413_CR14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/clinids\/19.4.741","volume":"19","author":"Larsen","year":"1994","unstructured":"Larsen RA, Bozzette SA, Jones BE (1994) Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 19(4):741\u2013745","journal-title":"Clin Infect Dis"},{"key":"1413_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jac\/dkf074","volume":"50","author":"Laverdiere","year":"2002","unstructured":"Laverdiere M, Hoban D, Restieri C, Habel F (2002) In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50:119\u2013123","journal-title":"J Antimicrob Chemother"},{"key":"1413_CR16","unstructured":"Lewis JS, Boucher HW, Lubowski T (2003) Economic advantage of voriconazole (VRC) for primary treatment of invasive aspergillosis compared to conventional amphotericin B (CAB) [abstract no. A-1359]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstracts, American Society for Microbiology; Sep 14\u201317; Chicago"},{"key":"1413_CR17","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","volume":"347","author":"Mora-Duarte","year":"2002","unstructured":"Mora-Duarte J, Betts R, Rotstein C (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020\u20132029","journal-title":"N Engl J Med"},{"key":"1413_CR18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF01575122","volume":"16","author":"Offner","year":"1997","unstructured":"Offner F (1997) Hematopoietic growth factors in cancer patients with invasive fungal infections. Eur J Clin Microbiol Infect Dis 16(1):56\u201363","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1413_CR19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","volume":"22","author":"Ostrosky-Zeichner","year":"2003","unstructured":"Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH (2003) Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22:651\u2013655","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1413_CR20","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","volume":"18","author":"Ozer","year":"2000","unstructured":"Ozer H, Armitage JO, Bennett CL et al. (2000) American Society of Clinical Oncology. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18(20):3558\u20133585","journal-title":"J Clin Oncol"},{"key":"1413_CR21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","volume":"36","author":"Perfect","year":"2003","unstructured":"Perfect JR, Marr KA, Walsh TJ (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122\u20131131","journal-title":"Clin Infect Dis"},{"key":"1413_CR22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jama.1996.03530270029027","volume":"275","author":"Pinner","year":"1996","unstructured":"Pinner RW, Teutsch SM, Simonsen L (1996) Trends in infectious diseases mortality in the United States. JAMA 275(3):189\u2013193","journal-title":"JAMA"},{"key":"1413_CR23","unstructured":"Stille W, Brodt HR, Groll AH, Just-N\u00fcbling G (2005) Antibiotika-Therapie, 11. Aufl. Schattaue, Stuttgart New York"},{"key":"1413_CR24","unstructured":"Tietz HJ, Sterry W (2002) Antimykotika von A\u2013Z, 2.\u00a0Aufl. Blackwell Wissenschafts-Verlag, Berlin Wien"},{"key":"1413_CR25","unstructured":"Ullmann AJ, Van Burik JA, McSweeney P (2003) An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Abstract 722. In: Proceedings of the 13th European Congress of Clinical Microbiology and Infectious Diseases 2003. Glasgow, UK"},{"key":"1413_CR26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","volume":"33","author":"Villanueva","year":"2001","unstructured":"Villanueva A, Arathoon EG, Gottuzzo E et al. (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33:1529\u20131535","journal-title":"Clin Infect Dis"},{"key":"1413_CR27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","volume":"346","author":"Walsh","year":"2002","unstructured":"Walsh TJ, Pappas P, Winston DJ (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346(4):225\u2013234","journal-title":"N Engl J Med"},{"key":"1413_CR28","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","volume":"351","author":"Walsh","year":"2004","unstructured":"Walsh TJ, Teppler H, Donowitz GR (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391\u20131402","journal-title":"N Engl J Med"},{"key":"1413_CR29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1524-4733.2002.51108.x","volume":"5","author":"Wilson","year":"2002","unstructured":"Wilson LS, Reyes CM, Stolpman M et al. (2002) The direct cost and incidence of systemic fungal infections. Value Health 5 (1):26\u201334","journal-title":"Value Health"},{"key":"1413_CR30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1396-0296.2004.04057.x","volume":"17","author":"Wu","year":"2004","unstructured":"Wu JJ, Pang KR, Huang DB, Tyring SK (2004) Therapy of systemic fungal infections. Dermatol Ther 17:532\u2013538","journal-title":"Dermatol Ther"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1413-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-005-1413-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-005-1413-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:11:32Z","timestamp":1558584692000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-005-1413-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s00108-005-1413-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}